Table 1.
Baseline characteristics
| Total, n = 78 | Responders, n = 62 | Non-responders, n = 16 | p | |
| Gender | 63M/15F | 49M/13F | 14M/2F | 0.72 |
| Age at referral | 66, 43–87 | 64, 43–87 | 71, 55–84 | 0.14 |
| Beta-adrenoceptor antagonists | 57 | 45 | 12 | 1.00 |
| Ca2+-channel antagonists | 35 | 24 | 11 | < 0.05 |
| Long-lasting nitrates | 58 | 45 | 15 | 0.10 |
| Warfarin | 6 | 4 | 2 | 0.60 |
| Aspirin | 67 | 53 | 14 | 1.00 |
| ACEI or ARB | 36 | 26 | 10 | 0.17 |
| Diuretics | 27 | 19 | 8 | 0.24 |
| Lipid lowering agents | 64 | 50 | 14 | 0.72 |
| Insulin | 11 | 7 | 4 | 0.22 |
| Oral antidiabetics | 8 | 3 | 5 | < 0.01 |
| Diabetes | 16 | 9 | 7 | < 0.02 |
| Hypertension | 26 | 19 | 7 | 0.38 |
| Atrial fibrillation | 3 | 2 | 1 | 0.50 |
| Current smoker | 3 | 3 | 0 | 1.00 |
| Myocardial infarction | 47 | 38 | 9 | 0.78 |
| CABG | 57 | 44 | 13 | 0.54 |
| PCI | 45 | 37 | 8 | 0.57 |
| CABG or PCI | 66 | 51 | 15 | 0.44 |
| Pacemaker | 6 | 3 | 3 | 0.10 |
| CCS IV | 12 | 10 | 2 | 0.46 |
| CCS III | 58 | 47 | 11 | |
| CCS II | 8 | 5 | 3 | |
| CCS I | 0 | 0 | 0 | |
| Years with CAD | 11.5, 1–35 | 11.5, 1–35 | 11, 2–33 | 0.98 |
| EF > 50% | 48 | 39 | 9 | 0.76 |
| EF 50 – 41% | 14 | 10 | 4 | |
| EF 40 – 30% | 14 | 11 | 3 | |
| EF < 30% | 2 | 2 | 0 |
EECP = enhanced external counterpulsation, ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin type I receptor blocker, CABG = coronary artery bypass graft, PCI = percutaneous coronary intervention, CCS = Canadian Cardiovascular Society classification, CAD = coronary artery disease, EF = ejection fraction.